CD4 and neoplasm: An EGFR‐Vδ2 bispecific T‐cell engagers (bsTCE) were developed to activate Vγ9Vδ2 T cells and selectively kill EGFR‐overexpressing tumor cells, which promoted the downstream activation of CD4+, CD8+ T cells and NK cells, but not Tregs.